Clinical Trials Directory

Trials / Unknown

UnknownNCT02794649

Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
VA New York Harbor Healthcare System · Federal
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

To characterize the microbiome in 4 groups of subjects (primary hyperoxaluria type I (PH1), idiopathic CaOx stone, enteric hyperoxaluria (EH) and healthy participants) by comparing the number of species and diversity of the microbial populations and pathway for oxalate metabolism by paralleling the gene expression of enzymes involved in oxalate degradation by gut bacteria.

Detailed description

Kidney stones affect as much as 10% of the US population with the most common type of stones made of calcium oxalate. Calcium and oxalate are present in the urine and can bind to each other, and form calcium oxalate kidney stones. Oxalate is absorbed in the gut from the food that is eaten and is removed from the body through urination. Gut bacteria is thought to play a role in decreasing oxalate absorption in the gut and its levels in the urine. With this research we hope to learn about differences in the bacteria that live in the gut of different groups of participants who are likely to form kidney stones, as well as healthy individuals. We will study healthy people with no history of kidney stones, people with a history of calcium oxalate (CaOx) kidney stones, people with a genetic disease called primary hyperoxaluria type1 (PH1) that increases their chances to form calcium oxalate kidney stones and, people with enteric hyperoxaluria (EH) a disease in which individuals have short bowels due to surgery which lead them to get calcium oxalate kidney stones. Our research questions are: 1. How different is the gut bacteria between participants with the conditions that make them more likely to form kidney stones and healthy participants with no history of kidney stones? 2. Is there any difference in the function of the individual bacteria, Oxalobacter formigenes known to reduce oxalate, between healthy participants with no history kidney stones and participants with PH1?

Conditions

Timeline

Start date
2016-06-01
Primary completion
2018-06-01
Completion
2018-06-01
First posted
2016-06-09
Last updated
2017-09-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02794649. Inclusion in this directory is not an endorsement.